Design and rationale of DUTCH-AF: a prospective nationwide registry programme and observational study on long-term oral antithrombotic treatment in patients with atrial fibrillation

Gordon Chu, Jaap Seelig, Emmy M. Trinks-Roerdink, Anouk P. van Alem, Marco Alings, Bart van den Bemt, Lucas Va Boersma, Marc A. Brouwer, Suzanne C. Cannegieter, Hugo Ten Cate, Charles Jhj Kirchhof, Harry Jgm Crijns, Ewoud J. van Dijk, Arif Elvan, Isabelle C. van Gelder, Joris R. de Groot, Frank R. den Hartog, Jonas Ssg de Jong, Sylvie de Jong, Frederikus A. KlokTimo Lenderink, Justin G. Luermans, Joan G. Meeder, Ron Pisters, Peter Polak, Michiel Rienstra, Frans Smeets, Giovanni Jm Tahapary, Luc Theunissen, Robert G. Tieleman, Serge A. Trines, Pepijn van der Voort, Geert Jan Geersing, Frans H. Rutten, Martin Ew Hemels, Menno V. Huisman

Research output: Contribution to journalArticleAcademicpeer-review

8 Downloads (Pure)


INTRODUCTION: Anticoagulation therapy is pivotal in the management of stroke prevention in atrial fibrillation (AF). Prospective registries, containing longitudinal data are lacking with detailed information on anticoagulant therapy, treatment adherence and AF-related adverse events in practice-based patient cohorts, in particular for non-vitamin K oral anticoagulants (NOAC). With the creation of DUTCH-AF, a nationwide longitudinal AF registry, we aim to provide clinical data and answer questions on the (anticoagulant) management over time and of the clinical course of patients with newly diagnosed AF in routine clinical care. Within DUTCH-AF, our current aim is to assess the effect of non-adherence and non-persistence of anticoagulation therapy on clinical adverse events (eg, bleeding and stroke), to determine predictors for such inadequate anticoagulant treatment, and to validate and refine bleeding prediction models. With DUTCH-AF, we provide the basis for a continuing nationwide AF registry, which will facilitate subsequent research, including future registry-based clinical trials. METHODS AND ANALYSIS: The DUTCH-AF registry is a nationwide, prospective registry of patients with newly diagnosed 'non-valvular' AF. Patients will be enrolled from primary, secondary and tertiary care practices across the Netherlands. A target of 6000 patients for this initial cohort will be followed for at least 2 years. Data on thromboembolic and bleeding events, changes in antithrombotic therapy and hospital admissions will be registered. Pharmacy-dispensing data will be obtained to calculate parameters of adherence and persistence to anticoagulant treatment, which will be linked to AF-related outcomes such as ischaemic stroke and major bleeding. In a subset of patients, anticoagulation adherence and beliefs about drugs will be assessed by questionnaire. ETHICS AND DISSEMINATION: This study protocol was approved as exempt for formal review according to Dutch law by the Medical Ethics Committee of the Leiden University Medical Centre, Leiden, the Netherlands. Results will be disseminated by publications in peer-reviewed journals and presentations at scientific congresses. TRIAL REGISTRATION NUMBER: Trial NL7467, NTR7706 (

Original languageEnglish
Article numbere036220
Pages (from-to)1-9
JournalBMJ Open
Issue number8
Publication statusPublished - 24 Aug 2020


Dive into the research topics of 'Design and rationale of DUTCH-AF: a prospective nationwide registry programme and observational study on long-term oral antithrombotic treatment in patients with atrial fibrillation'. Together they form a unique fingerprint.

Cite this